Defining a ‘cells to society’ research framework for appendiceal tumours
Andreana N. Holowatyj & colleagues on behalf of Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation
Andreana N. Holowatyj & colleagues on behalf of Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation
Targeted protein degradation (TPD) is an emerging pharmacological modality in cancer therapy. In this Review, Hinterndorfer et al. outline the mechanistic bases of TPD and discuss the characteristics, advantages and applications of established compounds as well as upcoming classes of degraders.